Is Rigel Pharmaceuticals, Inc. overvalued?

Rigel Pharmaceuticals, Inc. (RIGL) looks undervalued — trading about 151% below its fair value.

Undervalued

Price

$42.58

Fair value

$106.87

Current P/E

6.7

Normal P/E

16.9

Market cap

$787.8M

Dividend yield

0.0%

Return on equity

96.5%

Sector

Healthcare

Fair value compares RIGL's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.

Related stocks